We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Assay May Boost Treatment of Non-Hodgkin Lymphoma

By LabMedica International staff writers
Posted on 14 Nov 2017
Print article
Image: The Hitachi ABI 3130XL capillary electrophoresis genetic analyzer system (Photo courtesy of Cal-L enterprises).
Image: The Hitachi ABI 3130XL capillary electrophoresis genetic analyzer system (Photo courtesy of Cal-L enterprises).
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide. Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

DLBCL includes three major subtypes termed germinal center B-cell-like, activated B-cell-like, and primary mediastinal B-cell lymphoma. A reliable, accessible, rapid, and cost-effective new gene expression signature assay has been developed that can enhance lymphoma management by helping to match tumors with the appropriate targeted therapy.

A team of scientists working with those at the Centre Henri Becquerel (Rouen, France) collected a total of 218 biopsy samples, including fresh/frozen biopsies of 150 DLBCL cases had previously been analyzed using U133 + 2 GEP arrays. A total of 38 primary mediastinal B-cell lymphoma (PMBL) cases from another trial and 29 from the Center Henri Becquerel, were also included as well as 30 DLBCL cases from the same institution.

The investigators extracted RNA samples from formalin-fixed paraffin-embedded (FFPE) tissue using Siemens TPS and Versant reagents kit. Immunoperoxidase stains were performed on a Benchmark Ultra automated stainer using Ultraview Universal diaminobenzidine detection kits. A rapid and inexpensive reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay was developed that allows for an accurate classification of germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCLs. The resulting MLPA amplicons were analyzed by fragment analysis using an ABI 3130 XL capillary electrophoresis system.

The team tested 150 RNA samples extracted from biopsies and 42% of the samples had the ABC subtype, 37% the GCB subtype, and 10% molecular PMBL, while 11% of samples could not be classified. Overall, the RT-MLPA assay correctly assigned 85.0% of the cases into the expected subtypes compared to 78.8% with immunohistochemistry. The assay was also able to detect the MYD88 L265P mutation, one of the most common genetic abnormalities found in ABC DLBCLs. This information can influence treatment, since the presence of the mutation has been suggested to be predictive of ibrutinib sensitivity.

The authors concluded that RT-MLPA appears as an efficient, rapid, and cost-effective alternative to the current methods used in the clinic to establish the cell of origin classification of DLBCLs. In contrast to other technologic approaches its implementation requires only common laboratory equipment, that is, a thermal cycler and a capillary genetic analyzer, and does not necessitate the acquisition of any specialized platform. By allowing the identification of the three major DLBCL subtypes and a simultaneous evaluation of multiple prognostic and theranostic markers and therapeutic targets, RT-MLPA could contribute to a more efficient management of these aggressive tumors in both clinical trials and daily practice. The study was published in the November 2017 issue of the Journal of Molecular Diagnostics.

Related Links:
Centre Henri Becquerel

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Centromere B Assay
Centromere B Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.